Gainers

• Lunai Bioworks (NASDAQ:LNAI) stock increased by 147.7% to $0.52 during Tuesday's regular session. The company's market cap stands at $5.1 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 39.0% to $2.65. The market value of their outstanding shares is at $8.5 million. The company's, Q4 earnings came out 2 days ago.
• Edesa Biotech (NASDAQ:EDSA) stock increased by 38.84% to $7.11. The market value of their outstanding shares is at $42.7 million.
• AIxCrypto Holdings (NASDAQ:AIXC) shares moved upwards by 16.8% to $1.34. The company's market cap stands at $5.9 million.
• DocGo (NASDAQ:DCGO) shares increased by 16.75% to $0.76. The company's market cap stands at $63.3 million. The company's, Q4 earnings came out yesterday.
• X4 Pharmaceuticals (NASDAQ:XFOR) stock moved upwards by 16.01% to $4.13. The company's market cap stands at $311.2 million. The company's, Q4 earnings came out today.

Losers

• Aldeyra Therapeutics (NASDAQ:ALDX) shares decreased by 68.4% to $1.33 during Tuesday's regular session. The company's market cap stands at $254.4 million.
• LENSAR (NASDAQ:LNSR) stock fell 33.53% to $6.82. The market value of their outstanding shares is at $122.4 million.
• Agape ATP (NASDAQ:ATPC) stock fell 31.28% to $2.72. The company's market cap stands at $3.9 million.
• IM Cannabis (NASDAQ:IMCC) stock fell 26.44% to $0.58. The market value of their outstanding shares is at $4.6 million.
• ENvue Medical (NASDAQ:FEED) stock decreased by 24.58% to $1.38. The market value of their outstanding shares is at $1.9 million.
• Mainz Biomed (NASDAQ:QUCY) shares fell 18.01% to $0.57. The company's market cap stands at $8.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.